Find a Trial

Trial Results


24 protocol(s) meet the specified criteria
CTO-A011801OPEN TO ACCRUAL
THE COMPASSHER2 TRIALS (COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2-POSITIVE BREAST CANCER): COMPASSHER2 RESIDUAL DISEASE (RD), A DOUBLE-BLINDED, PHASE III RANDOMIZED TRIAL OF T-DM1 AND PLACEBO COMPARED WITH T-DM1 AND TUCATINIB
CTO-BRE18-334OPEN TO ACCRUAL
A Phase II circulating tumor DNA enriched, genomically directed post-neoadjuvant trial for patients with residual triple negative breast cancer (PERSEVERE)
CTO-CTMX-2009-002OPEN TO ACCRUAL
A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072 in Advanced Triple-Negative Breast Cancer (CTMX-2009-002)
CTO-EA1181OPEN TO ACCRUAL
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)
CTO-IUSCC-0718OPEN TO ACCRUAL
A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention program
CTO-IUSCCC-0758OPEN TO ACCRUAL
Targeting progesterone signaling for breast cancer prevention in BRCA1 carriers: a pilot study
CTO-M19-345OPEN TO ACCRUAL
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination with ABBV-181 in Subjects with Locally Advanced or Metastatic Solid Tumors
CTO-SWOG-S1904OPEN TO ACCRUAL
CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)
IUCRO-0209OPEN TO ACCRUAL
The Susan G. Komen Tissue Bank at the IU Simon Cancer Center: A Collection and Storage of Biological Specimens Intended for use in the Elucidation of Breast Carcinogenesis
IUSCC-0630OPEN TO ACCRUAL
COLLECTION OF SPECIMENS AND CLINICAL DATA TO CREATE A BIOREPOSITORY AND REGISTRY FOR INFLAMMATORY BREAST CANCER
IUSCC-0649OPEN TO ACCRUAL
Functional and Neurochemical Substrates of Chemotherapy-Related Cognitive Deficits
IUSCC-0659OPEN TO ACCRUAL
Assessing tobacco use and cessation support among patients with non-tobacco related cancers
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0706OPEN TO ACCRUAL
Facilitating Adaptive Coping with Fear of Recurrence Among Breast Cancer Survivors: A Three-Arm Randomized Controlled Trial (FACing Fear)
J11155OPEN TO ACCRUAL
Pre-Operative PARPi and Irradiation (POPI) in Women with an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer
J13104OPEN TO ACCRUAL
A Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0)
NURS-IIR-IUSCC-0748OPEN TO ACCRUAL
Biobehavioral correlates of cancer-related cognitive dysfunction and its co-occurring symptoms
RADY-ECOG-WESTPHAL-EA1151OPEN TO ACCRUAL
Tomosynthesis Mammographic Imaging Screening Trial (TMIST) EA1151
RADY-GU-SAYKIN-TLCOPEN TO ACCRUAL
Older Breast Cancer Patients: Risk for Cognitive Decline
RADY-IIR-CBTOPEN TO ACCRUAL
Mobile Device CBT for Chemotherapy-Related Cognitive Dysfunction: A Multi-Center Randomized Controlled Trial
RAON-CCTG-MA39OPEN TO ACCRUAL
A RANDOMIZED TRIAL OF REGIONAL RADIOTHERAPY IN BIOMARKER LOW RISK NODE POSITIVE BREAST CANCER
S1706OPEN TO ACCRUAL
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
TBCRC044OPEN TO ACCRUAL
A Randomized Phase II Study of Pembrolizumab, an anti-PD (programmed cell death)-1 Antibody, in Combination with Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease
TBCRC045OPEN TO ACCRUAL
A RANDOMIZED, PHASE II STUDY COMPARING TRASTUZUMAB AND VINORELBINE IN COMBINATION WITH AVELUMAB OR AVELUMAB AND UTOMILUMAB (41BB/CD137 AGONIST), IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER WHO HAVE PROGRESSED ON PRIOR TRASTUZUMAB AND PERTUZUMAB: The "AVIATOR Study